Terns Pharmaceuticals Inc (TERN)
Terns Highlights Additional Positive Phase 1 Clinical Data Supporting TERN-701’s Best-in-Disease Potential in Relapsed/Refractory CML at the 67th ASH Annual Meeting
Terns Highlights Additional Positive Phase 1 Clinical Data Supporting TERN-701’s Best-in-Disease Potential in Relapsed/Refractory CML at the 67th ASH Annual Meeting
📉 **NEGATIVE** • Medium confidence analysis (63%) • Mild negative clinical indicator • Limited downside risk **Sentiment:** Negative (20%) **Content type:** Clinical